New hope for kids with severe psoriasis: adalimumab trial launches
NCT ID NCT07529925
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug adalimumab in 30 Chinese children aged 4 to 17 with severe plaque psoriasis that hasn't improved with creams or light therapy. The goal is to see if adalimumab can safely reduce skin symptoms like redness and scaling. The main measure is how many children achieve at least a 75% improvement in their psoriasis by week 16.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- adalimumab (a drug that blocks inflammation)
- What this could lead to
- If successful, this could provide a safe and effective treatment option for Chinese children with severe plaque psoriasis who haven't responded to other therapies.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply to all children. Adalimumab can have side effects like increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
4 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects and their guardians must sign an informed consent form. The research protocol/informed consent form for data collection and data verification should comply with local laws and regulations. * Age 4 years ≤ age ≤ 17 years, regardless of gender; * Subjects weigh ≥ 15kg; * Subjects who respond poorly to local treatment and/or phototherapy or are unsuitable for such treatments; * Diagnosed with severe plaque psoriasis in children according to the "Chinese Expert Consensus on the Diagnosis and Treatment of Pediatric Psoriasis (2021)" Exclusion Criteria: * Based on the prescribing information of Adalimumab Solution for Injection and the judgment of the treating physician, the subject is not eligible for treatment with Adalimumab Solution for Injection; * Subjects who received psoralen combined with long-wave ultraviolet (UVA) therapy within 14 days prior to the screening period, or topical medium-wave ultraviolet (UVB) therapy within 7 days prior to the screening period; * Subjects who received non-biological systemic treatments for paediatric psoriasis within 14 days prior to the screening period; * Subjects who are currently using or have used other biological Disease-Modifying Antirheumatic Drug treatments within 12 weeks prior to the screening period; * Subjects with significantly active psoriasis within 12 weeks prior to enrolment; * Subjects who have received any live vaccine within 3 months prior to the first dose of Adalimumab Solution for Injection, or who plan to receive live vaccines during the study; * Subjects currently participating in other clinical studies; * Subjects deemed unsuitable for participation in this trial by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe plaque psoriasis in chinese children are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.